Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. UBS upgraded ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Solar stocks slid in off-hours trading after Senate Republicans kept in a full phase-out of solar and wind energy tax credits in [President Trump's budget bill]( ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...